Warnex is focused on providing contract laboratory services to the pharmaceutical and healthcare sectors. We are committed to quality and scientific excellence in all aspects of our business, and we have earned a reputation for providing reliable and consistent results as well as outstanding customer service. Our ultimate goal is to become a significant player in the laboratory services sector, through both acquisitions and organic growth. We have a strong track record of growth and we have acquired and successfully integrated five acquisitions in the laboratory sector.


Financial Summary

Revenues (‘000 $)21,09825,49925,78723,64722,251
Property, plant, equip. (‘000 $)10,9327,7268,3097,3766,174
Net earnings (‘000 $)(18,205)(1,597)2,373(164)(1,559)
Net earnings per share ($)(0.34)(0.03)0.040.00(0.02)

Latest news

December 20, 2011
Warnex to Sell Its Analytical Services Division
December 9, 2011
Warnex Sells Its Medical and Forensic Testing Operations to Gamma-Dynacare and Reaches Repayment Agreement With Its Debentureholders
November 29, 2011
Warnex Announces Resignation of Its President & CEO

> Go to news page

Stock Quote

TSX: WNX High: 0.05
Open: 0.05 Low: 0.04
52 week h/l:
0.02 - 0.11
Volume: 19,000
Canadian $
Quotes are delayed.

Fast Facts Q3 2011

Year-EndDec. 31
Employees 222
Shares Outstanding67.1 million
Market Capitalization $2.7 million


2010 Annual Report (PDF: 643 Kb)
Corporate presentation (PDF: 3.43 Mb)
Fact sheet (PDF: 120 Kb)